Navigation Links
Insulet Appoints Bill Arthur as Vice President of Business Development
Date:9/3/2008

ty payors for the OmniPod System and potential adverse changes in reimbursement rates or policies relating to the OmniPod; potential adverse effects resulting from competition with competitors; technological innovations adversely affecting the Company's business; potential termination of Insulet's license to incorporate a blood glucose meter into the OmniPod System; Insulet's ability to protect its intellectual property and other proprietary rights; conflicts with the intellectual property of third parties; adverse regulatory or legal actions relating to the OmniPod System; the potential violation of federal or state laws prohibiting "kickbacks" and false and fraudulent claims or adverse affects of challenges to or investigations into Insulet's practices under these laws; product liability lawsuits that may be brought against Insulet; unfavorable results of clinical studies relating to the OmniPod System or the products of Insulet's competitors; potential future publication of articles or announcement of positions by physician associations or other organizations that are unfavorable to Insulet's products; Insulet's ability to attract and retain key personnel; Insulet's ability to manage its growth; risks associated with potential future acquisitions; Insulet's ability to maintain compliance with the restrictions and covenants contained in its existing credit and security agreement; Insulet's ability to successfully maintain effective internal controls; and other risks and uncertainties described in the Company's annual report on Form 10-K for the year ended December 31, 2007 and in the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2008 and its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet u
'/>"/>
SOURCE Insulet Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Insulet Reports Second Quarter 2008 Results
2. Insulet Reports First Quarter 2008 Results
3. Insulet Corporation to Report Fourth Quarter and Full Year 2007 Financial Results on Monday, March 17
4. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
5. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
6. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
7. Landauer, Inc. Appoints Two New Members to Board of Directors
8. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
9. Regenerative Medicine Appoints Cell Therapy Group Consultant to Editorial Board
10. UltraShape Appoints Assaf Eyal as President & CEO
11. RHEI Pharmaceuticals Appoints Dr. Geert Cauwenbergh as Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 2015 Regis Technologies looks forward to ... Cancer Research (AACR) annual meeting. Regis will exhibit at ... Saturday, April 18, in Philadelphia and running through April ... of the oldest and largest organization focused on cancer ... and partners with survivors to promote awareness and research ...
(Date:4/16/2015)... , April 16, 2015  In recognition of World Hemophilia ... hemophilia advocacy groups to illuminate more than 15 prominent landmarks ... Boston,s Zakim Bridge and Prudential Tower, ... Orleans, Mercedes-Benz Superdome and Denver,s ... the evening of April 17, and coincide with hemophilia community ...
(Date:4/16/2015)... 16, 2015 ChemRar ... investment and R&D group, and Lancet, Russian ... development and commercialization of new medicines in ... intention to stimulate the innovative development of ... (Logo: http://photos.prnewswire.com/prnh/20150416/739742-a) ,     (Logo: http://photos.prnewswire.com/prnh/20150416/739742-b) , ...
(Date:4/16/2015)... Avelas Biosciences, an in vivo ... today that it has initiated a Phase 1b study ... with primary, non-recurrent breast cancer undergoing surgery. In commencing ... of Steven Chen , M.D., as vice president ... escalation study will enroll up to 39 women with ...
Breaking Biology Technology:Regis Technologies Joins American Association for Cancer Research Annual Meeting 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3
... Oct. 31, 2011 Neurocrine Biosciences, Inc. (NASDAQ: NBIX ... 30, 2011. For the third quarter of 2011, ... fully diluted share outstanding, compared to net income of $3.3 million, ... in 2010. For the nine months ended September 30, 2011, the ...
... (NYSE Amex: PIP ) announced today further ... SparVax™.  The new vaccine is being developed to provide ... emergency.  The Company completed its first cGMP manufacturing run ... ongoing and expected to be completed in December. ...
... Blood Pressure , aka Hypertension , is ... mostly ineffective.   Fortunately , Hypertensive patients ... methods that are both effective, inexpensive, and risk free. ... help reduce   Chronic Heart/Cardiovascular Disease patients,   ...
Cached Biology Technology:Neurocrine Biosciences Reports Third Quarter 2011 Results 2Neurocrine Biosciences Reports Third Quarter 2011 Results 3Neurocrine Biosciences Reports Third Quarter 2011 Results 4Neurocrine Biosciences Reports Third Quarter 2011 Results 5Neurocrine Biosciences Reports Third Quarter 2011 Results 6Neurocrine Biosciences Reports Third Quarter 2011 Results 7Neurocrine Biosciences Reports Third Quarter 2011 Results 8PharmAthene Progresses Second Generation rPA Anthrax Vaccine 2PharmAthene Progresses Second Generation rPA Anthrax Vaccine 3PharmAthene Progresses Second Generation rPA Anthrax Vaccine 4Drug-Free BLOOD PRESSURE Control & Medical "Take-Away" Treatment are Potential Win-Win Solutions in Health Care 2
(Date:4/13/2015)... April 13, 2015  higi, a leading cloud-based consumer ... more fully engage with their communities around health and ... protected and secure API.  ... most accessible, affordable, and convenient vehicle to receive validated ... The API will allow higi,s trusted ...
(Date:4/9/2015)... 9, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the third ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/143028 for MINIATURE, MULTI-PURPOSE ... TRANSFER  NXT-ID introduces a new revolutionary ... patent surrounds the use of miniature antenna modules ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... the October 2011 issue of Experimental Biology and ... Medical Center led by Stephen Tsang, MD, Ph.D have ... model for retinitis pigmentosa (RP) using novel bipartite gene ... by progressive degeneration of rod photoreceptors (which mediate night ...
... The carbon dioxide we exhale and the odors our skins ... hunt for human hosts to bite and spread diseases such ... at the University of California, Riverside have now performed experiments ... that transmit yellow fever and dengue -- respond to plumes ...
... Irvine, Calif., Sept. 30, 2011 A glucosamine-like dietary ... sclerosis, according to a UC Irvine study. UCI,s ... oral N-acetylglucosamine (GlcNAc), which is similar to but more ... and function of abnormal T-cells that in MS incorrectly ...
Cached Biology News:Cell-specific mechanism-based gene therapy approach to treat retinitis pigmentosa 2Cell-specific mechanism-based gene therapy approach to treat retinitis pigmentosa 3Flight patterns reveal how mosquitoes find hosts to transmit deadly diseases 2Glucosamine-like supplement suppresses multiple sclerosis attacks 2
Goat polyclonal to JIK ( Abpromise for all tested applications). Antigen: Synthetic peptide: HKKDHVFIRDEAGHGD, corresponding to amino acids 396-411 of Human JIK. Entrez Gene ID: 51347 Swi...
Chicken polyclonal to DCTD ( Abpromise for all tested applications). Antigen: Full length protein (Human) Entrez GeneID: 1635 Swiss Protein ID: P32321...
Rab 3 Immunogen: Synthetic peptide corresponding to the N-terminal region of Rab 3 protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
Biology Products: